早期非小细胞肺癌立体定向放疗后放射性第二肿瘤风险估算
回顾性选取10例早期非小细胞肺癌患者,比较3D-CRT、螺旋断层放疗和VMAT计划的第二肺癌与乳腺癌超额绝对风险。结果显示在30至70 Gy处方剂量范围内,旋转调强技术虽机器跳数更高,但肺与乳腺平均EAR与3D-CRT相当,未增加第二肿瘤风险。
要点
- 旋转调强技术(HT/VMAT)未增加肺与乳腺第二肿瘤风险。
- 3D-CRT同侧肺第二肿瘤风险显著更高,对侧肺风险更低。
- 第二肿瘤风险随平均器官剂量近似线性增加。
核心结论
- 螺旋断层放疗和VMAT等旋转调强技术尽管机器跳数更高,但相比3D-CRT未增加肺或乳腺的第二肿瘤风险。
研究设计与样本
- 回顾性选取10例(5男5女)接受根治性立体定向体部放疗的早期非小细胞肺癌患者。
- 每例生成5种计划:6 MV和10 MV的3D-CRT各一、螺旋断层放疗一、1弧和2弧VMAT各一。
- 采用线性指数模型、平台模型和线性模型3种器官等效剂量模型估算第二肿瘤超额绝对风险,处方剂量范围30至70 Gy。
主要发现
- 3D-CRT计划的机器跳数显著低于旋转调强放疗计划。
- 基于3种器官等效剂量模型,在30至70 Gy处方剂量范围内,HT和VMAT计划肺与乳腺的平均EAR与3D-CRT计划相当。
- 处方剂量50 Gy、线性指数模型下,5种技术的平均肺EAR为每年每万例15.7±5.3至16.0±6.5,乳腺平均EAR为每年每万例18.0±14.0至21.0±15.0。
- 第二肿瘤风险随平均器官剂量近似线性增加。
- 3D-CRT计划同侧肺第二肿瘤风险显著高于HT和VMAT计划,对侧肺风险更低。
临床怎么用
- 选择SBRT技术时,旋转调强技术未显示增加肺或乳腺第二肿瘤风险,可作为3D-CRT的合理替代。
- 评估第二肿瘤风险时应关注平均器官剂量,其与风险近似线性相关。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this study, we evaluated radiation-induced secondary lung cancer risks for the lung and the breast from stereotactic body radiation therapy treatment of early-stage non-small cell lung cancer with different radiation therapy treatment modalities. METHODS AND MATERIALS: Ten patients (5 men and 5 women) with early-stage non-small cell lung cancer who received definitive stereotactic body radiation therapy treatments were retrospectively selected. For each patient, two 3-dimensional conformal radiation therapy (3D-CRT) plans using 6- and 10-MV photons, respectively; a helical tomotherapy (HT) plan; and 2 volumetric modulated arc therapy (VMAT) plans using 1 and 2 arcs, respectively, were generated. The excess absolute risk (EAR) for secondary cancer occurrence was calculated using 3 organ equivalent dose models: the linear-exponential model, the plateau model, and the linear model for prescription dose range of 30 to 70 Gy. RESULTS: The 3D-CRT plans showed significantly lower monitor units compared with the rotational intensity modulate radiation therapy plans. Based on each of the 3 organ equivalent dose models, HT and VMAT plans showed comparable average EARs to both the lung and the breast compared with the 3D-CRT plans in the prescription dose range of 30 to 70 Gy. At a prescription dose of 50 Gy and using the linear-exponential model, the average lung EAR estimation ranged from 15.7 ± 5.3 to 16.0 ± 6.5 per 10,000 patients per year with the 5 delivery techniques, and the average EAR estimation for the breast ranged from 18.0 ± 14.0 to 21.0 ± 15.0 per 10,000 patients per year. The secondary cancer risk increased approximately linearly with mean organ dose. The 3D-CRT plans showed significantly higher secondary cancer risk for the ipsilateral lung and lower risk for the contralateral lung compared with the HT and VMAT plans. CONCLUSIONS: Rotational intensity modulate radiation therapy techniques including helical tomotherapy and VMAT do not increase secondary cancer risks for the lung or the breast compared with 3D-CRT techniques, despite higher monitor units used.
引用
- Han C, Schultheiss TE, Wong JYC, et al. Estimation of radiation-induced secondary cancer risks for early-stage non-small cell lung cancer patients after stereotactic body radiation therapy. Pract Radiat Oncol. 2016. PMID: 28089479. doi:10.1016/j.prro.2016.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。